A Phase II, Randomized, Double-Blind, Double-Dummy, Active-Controlled Clinical Trial to Investigate the Efficacy and Safety of NW Low-Glu® in Patients Newly Diagnosed with Type 2 Diabetes Mellitus

Table 5

Binary logistic regression analysis of diabetic patients achieving target HbA1c < 7%.

Variables	B	Wald.	value	OR	95% CI
					Lower	Upper
Baseline HbA1c (%)	−0.203	1.3	0.2	0.817	0.579	1.151
Fasting plasma glucose (mg/dL)	0.007	1.2	0.2	1.007	0.995	1.019
2h-post prandial glucose (mg/dL)	−0.010	7.02	0.008	0.990	0.983	0.997
HOMA-β	0.011	5.5	0.02	1.011	1.002	1.020
Diabetes duration (months)	0.094−	11.4	0.001	0.910	0.862	0.961
Patients’ weight (Kg)	0.024	1.5	0.2	1.024	0.987	1.063

The logistic regression model was statistically significant, revealed ; the model showed prediction accuracy with 75.7%.